AEON — Aeon Biopharma Cashflow Statement
0.000.00%
- $10.42m
- $25.05m
Annual cashflow statement for Aeon Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|
Period Length: | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K/A |
Standards: | USG | USG | USG |
Status: | Final | Final | Final |
Net Income/Starting Line | -55.6 | -52.6 | -385 |
Depreciation | |||
Non-Cash Items | 25.8 | 10.6 | 339 |
Unusual Items | |||
Other Non-Cash Items | |||
Changes in Working Capital | 1.42 | 6.27 | -2.74 |
Change in Prepaid Expenses | |||
Change in Accounts Payable | |||
Change in Accrued Expenses | |||
Net Change in Other Assets & Liabilities | |||
Cash from Operating Activities | -28.4 | -35.6 | -47.8 |
Capital Expenditures | -0.17 | -0.306 | 0 |
Purchase of Fixed Assets | |||
Cash from Investing Activities | -0.17 | -0.306 | 0 |
Financing Cash Flow Items | -1.44 | 0 | — |
Other Financing Cash Flow | |||
Net Issuance / Retirement of Debt | |||
Cash from Financing Activities | 13.6 | 40.5 | 14 |
Beginning Cash Balance | |||
Ending Cash Balance | |||
Net Change in Cash | -15 | 4.62 | -33.8 |